請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78752
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 王錦堂(Jin-Town Wang) | |
dc.contributor.author | Ching-Yu Chiu | en |
dc.contributor.author | 邱淨妤 | zh_TW |
dc.date.accessioned | 2021-07-11T15:16:53Z | - |
dc.date.available | 2022-08-28 | |
dc.date.copyright | 2019-08-28 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-07-23 | |
dc.identifier.citation | 1. Weinstock GM. Genomic approaches to studying the human microbiota. Nature. 2012;489(7415):250-6.
2. Marchesi JR. Human distal gut microbiome. Environ Microbiol. 2011;13(12):3088-102. 3. Marchandin H, Damay A, Roudiere L, Teyssier C, Zorgniotti I, Dechaud H, Jean-Pierre H, and Jumas-Bilak E. Phylogeny, diversity and host specialization in the phylum Synergistetes with emphasis on strains and clones of human origin. Res Microbiol. 2010;161(2):91-100. 4. Ley RE, Turnbaugh PJ, Klein S, and Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022-3. 5. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, and Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-31. 6. Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, Glickman JN, Siebert R, Baron RM, Kasper DL, et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science. 2012;336(6080):489-93. 7. Candela M, Perna F, Carnevali P, Vitali B, Ciati R, Gionchetti P, Rizzello F, Campieri M, and Brigidi P. Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol. 2008;125(3):286-92. 8. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, Tobe T, Clarke JM, Topping DL, Suzuki T, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature. 2011;469(7331):543-7. 9. Kau AL, Ahern PP, Griffin NW, Goodman AL, and Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature. 2011;474(7351):327-36. 10. Dicksved J, Halfvarson J, Rosenquist M, Jarnerot G, Tysk C, Apajalahti J, Engstrand L, and Jansson JK. Molecular analysis of the gut microbiota of identical twins with Crohn's disease. ISME J. 2008;2(7):716-27. 11. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, and Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104(34):13780-5. 12. Gonzalez A, Stombaugh J, Lozupone C, Turnbaugh PJ, Gordon JI, and Knight R. The mind-body-microbial continuum. Dialogues Clin Neurosci. 2011;13(1):55-62. 13. Lupton JR. Microbial degradation products influence colon cancer risk: the butyrate controversy. J Nutr. 2004;134(2):479-82. 14. Murray CJL, and Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349(9063):1436-42. 15. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480-6. 16. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133(4):e38-360. 17. Nichols M, Townsend N, Scarborough P, and Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J. 2014;35(42):2950-9. 18. Reddy KS. Cardiovascular disease in non-Western countries. N Engl J Med. 2004;350(24):2438-40. 19. Khang YH, Lynch JW, and Kaplan GA. Impact of economic crisis on cause-specific mortality in South Korea. Int J Epidemiol. 2005;34(6):1291-301. 20. Cheng Y, Chen KJ, Wang CJ, Chan SH, Chang WC, and Chen JH. Secular trends in coronary heart disease mortality, hospitalization rates, and major cardiovascular risk factors in Taiwan, 1971-2001. Int J Cardiol. 2005;100(1):47-52. 21. Cassar A, Holmes DR, Jr., Rihal CS, and Gersh BJ. Chronic coronary artery disease: diagnosis and management. Mayo Clin Proc. 2009;84(12):1130-46. 22. Lim GB. Global burden of cardiovascular disease. Nat Rev Cardiol. 2013;10(2):59. 23. Jespersen L, Hvelplund A, Abildstrøm SZ, Pedersen F, Galatius S, Madsen JK, Jørgensen E, Kelbæk H, and Prescott E. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. European Heart Journal. 2012;33(6):734-44. 24. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685-95. 25. Diamond GA. A clinically relevant classification of chest discomfort. J Am Coll Cardiol. 1983;1(2 Pt 1):574-5. 26. Kandaswamy E, and Zuo L. Recent Advances in Treatment of Coronary Artery Disease: Role of Science and Technology. Int J Mol Sci. 2018;19(2). 27. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576-85. 28. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57-63. 29. Bodea S, Funk MA, Balskus EP, and Drennan CL. Molecular Basis of C-N Bond Cleavage by the Glycyl Radical Enzyme Choline Trimethylamine-Lyase. Cell Chem Biol. 2016;23(10):1206-16. 30. Jameson E, Quareshy M, and Chen Y. Methodological considerations for the identification of choline and carnitine-degrading bacteria in the gut. Methods. 2018;149(42-8. 31. Koeth RA, Lam-Galvez BR, Kirsop J, Wang Z, Levison BS, Gu X, Copeland MF, Bartlett D, Cody DB, Dai HJ, et al. l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. J Clin Invest. 2019;129(1):373-87. 32. Schugar RC, and Brown JM. Emerging roles of flavin monooxygenase 3 in cholesterol metabolism and atherosclerosis. Curr Opin Lipidol. 2015;26(5):426-31. 33. Chalmers RA, Bain MD, Michelakakis H, Zschocke J, and Iles RA. Diagnosis and management of trimethylaminuria (FMO3 deficiency) in children. J Inherit Metab Dis. 2006;29(1):162-72. 34. Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, Gu X, Huang Y, Zamanian-Daryoush M, Culley MK, et al. Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis. Cell. 2015;163(7):1585-95. 35. Wu W-K, Chen C-C, Liu P-Y, Panyod S, Liao B-Y, Chen P-C, Kao H-L, Kuo H-C, Kuo C-H, Chiu THT, et al. Identification of TMAO-producer phenotype and host–diet–gut dysbiosis by carnitine challenge test in human and germ-free mice. Gut. 2019;68(8):1439. 36. Behjati S, and Tarpey PS. What is next generation sequencing? Arch Dis Child Educ Pract Ed. 2013;98(6):236-8. 37. van Dijk EL, Auger H, Jaszczyszyn Y, and Thermes C. Ten years of next-generation sequencing technology. Trends Genet. 2014;30(9):418-26. 38. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, Berka J, Braverman MS, Chen Y-J, Chen Z, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature. 2005;437(376. 39. Magoc T, and Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics. 2011;27(21):2957-63. 40. Moody L, He H, Pan YX, and Chen H. Methods and novel technology for microRNA quantification in colorectal cancer screening. Clin Epigenetics. 2017;9(119. 41. Van de Peer Y, Chapelle S, and De Wachter R. A quantitative map of nucleotide substitution rates in bacterial rRNA. Nucleic Acids Res. 1996;24(17):3381-91. 42. Chakravorty S, Helb D, Burday M, Connell N, and Alland D. A detailed analysis of 16S ribosomal RNA gene segments for the diagnosis of pathogenic bacteria. J Microbiol Methods. 2007;69(2):330-9. 43. Barb JJ, Oler AJ, Kim HS, Chalmers N, Wallen GR, Cashion A, Munson PJ, and Ames NJ. Development of an Analysis Pipeline Characterizing Multiple Hypervariable Regions of 16S rRNA Using Mock Samples. PLoS One. 2016;11(2):e0148047. 44. Bird IM. High performance liquid chromatography: principles and clinical applications. BMJ. 1989;299(6702):783-7. 45. Craciun S, and Balskus EP. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc Natl Acad Sci U S A. 2012;109(52):21307-12. 46. Goodman AL, Kallstrom G, Faith JJ, Reyes A, Moore A, Dantas G, and Gordon JI. Extensive personal human gut microbiota culture collections characterized and manipulated in gnotobiotic mice. Proc Natl Acad Sci U S A. 2011;108(15):6252-7. 47. Noguchi K, Tsukumi K, and Urano T. Qualitative and quantitative differences in normal vaginal flora of conventionally reared mice, rats, hamsters, rabbits, and dogs. Comp Med. 2003;53(4):404-12. 48. Singhal N, Kumar M, Kanaujia PK, and Virdi JS. MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis. Front Microbiol. 2015;6(791. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78752 | - |
dc.description.abstract | 目前已知腸道菌叢(gut microbiota)會影響人類健康,最近也有報告顯示腸道菌叢與冠狀動脈疾病(coronary artery disease, CAD)相關,因此我們想建立腸道菌叢的培養體系統(culturomic system)以了解冠狀動脈疾病。
我們利用高登培養基(Gordon’s medium)以及伊藤培養基(Itoh’s medium)的5種非選擇性培養基(non-selective medium)和11種選擇性培養基(selective medium)進行健康人腸道菌叢之培養,發現高登培養基及非選擇性培養基可培養出較多菌種。再利用選擇性培養基分離出有興趣的菌種,結果分離菌種效率只有60%以下。另外,比較檢體收集後的貯存方式,結果發現冷凍檢體可培養出新鮮檢體30%-70%菌種。以細菌16S核醣體DNA定序(bacterial 16S ribosomal DNA sequencing)鑑定菌種,發現比基質輔助雷射脫附游離飛行時間質譜儀(MALDI-TOF)的鑑定效果佳。 我們的合作實驗室研究發現,給予健康受試者左旋肉鹼(L-carnitine)後,挑選出14位在血漿中測量到較高濃度的氧化三甲胺(trimethylamine-N-oxide, TMAO),之後利用細菌16S核醣體DNA定序分析,發現其腸道菌叢中有較高比例的瘤胃球菌屬(Ruminococcus)、毛螺菌科(Lachnospiraceae)、柔膜菌綱(Mollicutes)腸道菌。他們也利用宏基因組定序(shotgun metagenomic sequencing)方式,發現Odoribacter splanchnicus、Ruminococcus bicirculans、Bacteroides cellulosilyticus高度存在於TMAO濃度較高的健康受試者腸道菌叢中,且三者皆帶有cutC、cutD基因。 由於無法培養分離Ruminococcus bicirculans,為了釐清CutC和CutD蛋白質是否能夠將左旋肉鹼代謝成三甲胺(trimethylamine, TMA),將Ruminococcus bicirculans的cutC和cutD基因克隆到大腸桿菌並表現。萃取V14受試者糞便中的gDNA,以此作為模板進行聚合酶連鎖反應(PCR),將Ruminococcus bicirculans的cutC和cutD基因放大後接在表現載體pET28c上並轉型到大腸桿菌BL21(DE3),結果發現Ruminococcus bicirculans的CutC和CutD無法將d9-choline、d9-carnitine代謝產生γ-丁基甜菜鹼(γ-butyrobetaine, γBB)或TMA。 總結,冷凍方式貯存糞便檢體為方便且是檢體收集的替代方法;高登培養基及伊藤非選擇性培養基為較好的腸道菌叢培養基;細菌16S核醣體DNA定序是準確性高的方法。以大腸桿菌表現Ruminococcus bicirculans的cutC和cutD並無功能。 | zh_TW |
dc.description.abstract | It is currently known that gut microbiota affects human health, and recent research have shown that intestinal flora is associated with coronary artery disease (CAD). Therefore, we aim to establish a culturomic system of human gut microbiota to understand the association of human gut microbiota with CAD.
We cultured human gut microbiota from healthy volunteer’s stools by Gordon's medium and Itoh's medium which included 5 non-selective media and 11 selective media. The result showed that Gordon's medium and non-selective media cultivated more species than other did. Next, we used selective media to isolate specific species from cultivated gut microbiota, the efficiency of isolation is below 60%. In addition, comparing the storage methods for stool sample, we found that the culture rate from the frozen sample was 30%-70% compared with that from the fresh sample. Bacterial 16S ribosomal DNA sequencing is better than matrix-assisted laser desorption free time-of-flight mass spectrometer (MALDI-TOF) for the bacterial species identification. Our co-laboratory found that healthy subjects challenged with L-carnitine, 14 of them with high concentrations of trimethylamine-N-oxide (TMAO) in plasma were detected, and a high proportion of Ruminococcus, Lachnospiraceae, Mollicutes in their gut microbiota were analyzed by bacterial 16S ribosomal DNA sequencing. Moreover, they also found a high proportion of Odoribacter splanchnicus, Ruminococcus bicirculans, Bacteroides cellulosilyticus and all of them harbored cutC and cutD genes in high TMAO producers’ gut microbiota by shotgun metagenomic sequencing. We are unable to culture and isolate Ruminococcus bicirculans. To delineate whether the CutC and CutD proteins were able to metabolize L-carnitine to trimethylamine(TMA), the cutC and cutD genes of Ruminococcus bicirculans were cloned and expressed in Escherichia coli. The gDNA from the feces of the V14 subject was extracted and then as the template for PCR. The cutC and cutD genes of Ruminococcus bicirculans were amplified and ligated into the expression vector pET28c and transformed to E. coli BL21 (DE3). Our results found that CutC and CutD of Ruminococcus bicirculans were not able to metabolize d9-choline and d9-carnitine to γ-butyrobetaine (γBB) or TMA. In summary, frozen stool sample is a convenient and an alternative method for sample collections; Gordon’s medium and Itoh’s non-selective media are the better media for culture of human gut microbiota; bacterial 16S ribosomal DNA sequencing is an accurate method for identification. The cutC and cutD genes of Ruminococcus bicirculans have no function in E. coli BL21 (DE3). | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T15:16:53Z (GMT). No. of bitstreams: 1 ntu-108-R06445116-1.pdf: 3516732 bytes, checksum: 46dbb48164b48f5e75aa76afff8479d5 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口委審定書 I
致謝 II 中文摘要 III Abstract V 目錄 VII 圖目錄 X 表目錄 XI 第一章 緒論 1 1.1 腸道菌叢(gut microbiota) 1 1.2 冠狀動脈疾病(coronary artery disease, CAD) 1 1.2.1 冠狀動脈疾病簡介 1 1.2.2 冠狀動脈疾病與人類腸道菌叢關聯性 2 1.3 次世代定序(Next Generation Sequencing, NGS) 3 1.3.1 次世代定序簡介 3 1.3.2 微生物體16S擴增子定序 (16S Amplicon Sequencing) 4 1.4 高效液相層析儀(High performance liquid chromatography, HPLC) 5 1.5 研究動機 5 第二章 實驗方法 7 2.1 材料 7 2.1.1 健康人之糞便檢體 7 2.1.2 健康受試者之糞便檢體 7 2.1.3 高登培養基 7 2.1.4 引子(Primers) 7 2.2 方法 7 2.2.1 從糞便檢體培養出腸道菌叢 7 2.2.2 序列稀釋分離菌種 7 2.2.3 腸道菌叢提取gDNA 8 2.2.4 菌落聚合酶連鎖反應(colony PCR) 8 2.2.5 基質輔助雷射脫附游離飛行時間質譜儀(MALDI-TOF) 9 2.2.6 Uncultured Ruminococcus之三甲胺測定(TMA assay) 9 2.2.7 從糞便檢體提取gDNA 10 2.2.8 勝任細胞(competent cells)的製備 11 2.2.9 表現Ruminococcus bicirculans之CutC/D蛋白質 11 2.2.10 以Escherichia coli BL21(DE3)表現Ruminococcus bicirculans之CutC/D進行三甲胺測定(TMA assay) 13 2.2.11 聚丙烯醯胺膠體電泳(Sodium dodecyl sulfate-Polyacrylamide gel electrophoresis;SDS-PAGE)與蛋白質染色(Coomassie blue staining) 14 第三章 實驗結果 17 3.1 以不同培養基培養之健康人類腸道菌叢 17 3.2 以不同保存檢體方式培養之健康人腸道菌叢 17 3.3 以基質輔助雷射脫附游離飛行時間質譜儀鑑定菌種 17 3.4 以細菌16S核醣體DNA定序(bacterial 16S ribosomal DNA sequencing)鑑定菌種 18 3.5 以不同培養基分離菌種 18 3.6 以16S ribosomal DNA序列設計專一性引子分離高三甲胺產生表型之相關菌種 18 3.7 分析高登培養基培養之腸道菌叢 19 3.8 Uncultured Ruminococcus之三甲胺測定 19 3.9 以cutC、cutD基因設計引子尋找Ruminococcus bicirculans 20 3.10 將Ruminococcus bicirculans cutC/D基因送入pET-28c 20 3.11 以Escherichia coli BL21(DE3)表現Ruminococcus bicirculans之CutC/D蛋白質 21 3.12 以Escherichia coli BL21(DE3)表現Ruminococcus bicirculans之CutC/D進行三甲胺測定 21 第四章 討論 22 第五章 參考文獻 52 附錄 55 | |
dc.language.iso | zh-TW | |
dc.title | 建立培養體系統及分離高三甲胺產生表型之相關菌種 | zh_TW |
dc.title | Development of a culturomic system and isolation of bacterial species associated with high trimethylamine(TMA) producing phenotype | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 潘怡均(Yi-Chun Pang),賴信志(Hsin-Chih Lai) | |
dc.subject.keyword | 冠狀動脈疾病,腸道菌叢,Ruminococcus bicirculans,左旋肉鹼,氧化三甲胺, | zh_TW |
dc.subject.keyword | Coronary artery disease,Gut microbiota,Ruminococcus bicirculans,L-carnitine,Trimethylamine-N-oxide, | en |
dc.relation.page | 57 | |
dc.identifier.doi | 10.6342/NTU201901050 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-07-24 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-R06445116-1.pdf 目前未授權公開取用 | 3.43 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。